Zai Lab Limited - American Depositary Shares (ZLAB) closed at $22.11 on November 18, 2026, down 6.0% from the previous close, on volume of 888,972 shares (30-day average 1,085,500).
Data as of November 18, 2026.
18-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 17, 2026. See the largest for 5, 30, 60 and 90 days
Zai Lab Earnings Call Highlights Zoci Momentum and 2027 Catalysts
TipRanks (Sat, 14-Nov 8:34 PM ET)
Business Wire (Fri, 13-Nov 10:26 PM ET)
Zai Lab Announces Participation in Investor Conferences in November 2026
Business Wire (Fri, 13-Nov 4:35 PM ET)
Business Wire (Fri, 13-Nov 7:00 AM ET)
Business Wire (Thu, 5-Nov 9:00 AM ET)
Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates
Business Wire (Thu, 5-Nov 6:30 AM ET)
Market Chameleon (Fri, 23-Oct 3:05 AM ET)
Business Wire (Fri, 23-Oct 6:33 AM ET)
Zai Lab Announces $250 Million Private Placement
Business Wire (Thu, 22-Oct 8:52 PM ET)
Business Wire (Wed, 21-Oct 7:30 AM ET)
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Zai Lab Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol ZLAB.
As of November 18, 2026, ZLAB stock price declined to $22.11 with 888,972 million shares trading.
ZLAB has a beta of 1.37, meaning it tends to be more sensitive to market movements. ZLAB has a correlation of 0.10 to the broad based SPY ETF.
ZLAB has a market cap of $2.76 billion. This is considered a Mid Cap stock.
Last quarter Zai Lab Limited - American Depositary Shares reported $108 million in Revenue and -$.04 earnings per share. This beat revenue expectation by $284,480 and exceeded earnings estimates by $.54.
In the last 3 years, ZLAB traded as high as $44.34 and as low as $13.48.
The top ETF exchange traded funds that ZLAB belongs to (by Net Assets): IBB, CANC, SBIO, BBP, PGJ.
ZLAB has underperformed the market in the last year with a return of +5.7%, while the SPY ETF gained +10.8%. In the last 3 month period, ZLAB fell short of the market, returning -13.8%, while SPY returned -5.3%. However, in the most recent 2 weeks ZLAB has outperformed the stock market by returning +0.7%, while SPY returned -3.2%.
ZLAB support price is $22.57 and resistance is $24.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZLAB shares will trade within this expected range on the day.